Charles Schwab’s Cellectar Biosciences CLRB Stock Holding History

Charles Schwab’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-76	Closed	-$37K	–	3435
2021 Q1	$37K	Buy	+76	New	+$45.2K	﹤0.01%	3471

Other funds holding CLRB

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Charles Schwab's CLRB Position: Q2 2021 in Review

Charles Schwab sold out of Cellectar Biosciences (CLRB) in Q2 2021, closing a stake of 76 shares — an estimated $37K sold.

Charles Schwab first reported a position in CLRB in Q1 2021 and held it in 1 quarter. The position peaked at $37K in Q1 2021. 43 funds tracked by Wall St. Rank hold CLRB as of Q2 2021.

Charles Schwab reported no remaining Cellectar Biosciences position as of Q2 2021 after selling out during the quarter.
Charles Schwab sold 76 Cellectar Biosciences shares in Q2 2021, an estimated $37K.
Charles Schwab first reported a position in Cellectar Biosciences in Q1 2021 and held it in 1 quarter.
Charles Schwab's Cellectar Biosciences position peaked at $37K in Q1 2021.
43 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.